KOREA PHARMA Co., Ltd. (KOSDAQ:032300)
South Korea · Delayed Price · Currency is KRW 14,110
-30 (-0.21%)
At close: Sep 17, 2025
KOREA PHARMA Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 85,338 | 81,277 | 83,240 | 81,029 | 79,577 | 71,510 | Upgrade |
Other Revenue | - | - | -0 | -0 | - | - | Upgrade |
| 85,338 | 81,277 | 83,240 | 81,029 | 79,577 | 71,510 | Upgrade | |
Revenue Growth (YoY) | 6.14% | -2.36% | 2.73% | 1.83% | 11.28% | 8.13% | Upgrade |
Cost of Revenue | 50,761 | 46,127 | 46,337 | 45,614 | 43,679 | 37,365 | Upgrade |
Gross Profit | 34,576 | 35,150 | 36,903 | 35,415 | 35,898 | 34,145 | Upgrade |
Selling, General & Admin | 26,052 | 25,031 | 25,938 | 24,983 | 24,502 | 21,802 | Upgrade |
Research & Development | 2,204 | 2,053 | 2,313 | 2,452 | 4,893 | 6,221 | Upgrade |
Other Operating Expenses | 536.95 | 530.99 | 561.44 | 622.52 | 611.61 | 542.74 | Upgrade |
Operating Expenses | 30,642 | 29,064 | 31,063 | 29,228 | 30,883 | 29,541 | Upgrade |
Operating Income | 3,934 | 6,086 | 5,840 | 6,187 | 5,014 | 4,604 | Upgrade |
Interest Expense | -3,153 | -2,880 | -3,738 | -3,867 | -908.17 | -435.67 | Upgrade |
Interest & Investment Income | 927.26 | 1,397 | 510.74 | 211.94 | 57.42 | 17.28 | Upgrade |
Earnings From Equity Investments | 1,595 | 1,644 | -1,724 | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | -17.11 | 162.72 | -39.62 | 26.82 | 18.41 | -43.66 | Upgrade |
Other Non Operating Income (Expenses) | -2,589 | -2,590 | -139.55 | -4,378 | 1,019 | -382.76 | Upgrade |
EBT Excluding Unusual Items | 697.39 | 3,820 | 710.03 | -1,819 | 5,201 | 3,759 | Upgrade |
Gain (Loss) on Sale of Investments | 383.21 | 364.1 | 1,910 | -42.2 | 1.93 | 9.11 | Upgrade |
Gain (Loss) on Sale of Assets | 1.14 | 1.14 | 0.32 | 81.9 | 5.29 | - | Upgrade |
Asset Writedown | - | -279.24 | -606.42 | - | - | - | Upgrade |
Pretax Income | 1,082 | 3,906 | 2,014 | -1,780 | 5,208 | 3,768 | Upgrade |
Income Tax Expense | -366.76 | 114.21 | 1,931 | -660.63 | -1,160 | 608.75 | Upgrade |
Net Income | 1,448 | 3,792 | 83.76 | -1,119 | 6,368 | 3,159 | Upgrade |
Net Income to Common | 1,448 | 3,792 | 83.76 | -1,119 | 6,368 | 3,159 | Upgrade |
Net Income Growth | -51.63% | 4426.69% | - | - | 101.59% | -42.85% | Upgrade |
Shares Outstanding (Basic) | 11 | 11 | 10 | 11 | 11 | 10 | Upgrade |
Shares Outstanding (Diluted) | 12 | 12 | 10 | 11 | 11 | 10 | Upgrade |
Shares Change (YoY) | 16.03% | 15.33% | -3.63% | -1.22% | 12.80% | 10.95% | Upgrade |
EPS (Basic) | 132.69 | 347.65 | 8.00 | -103.00 | 584.00 | 324.00 | Upgrade |
EPS (Diluted) | 132.69 | 347.65 | 8.00 | -103.00 | 579.00 | 324.00 | Upgrade |
EPS Growth | -53.85% | 4245.66% | - | - | 78.70% | -48.49% | Upgrade |
Free Cash Flow | -17,951 | 4,797 | 3,288 | 5,815 | 4,640 | -2,848 | Upgrade |
Free Cash Flow Per Share | -1485.29 | 397.22 | 314.06 | 535.19 | 421.87 | -292.05 | Upgrade |
Gross Margin | 40.52% | 43.25% | 44.33% | 43.71% | 45.11% | 47.75% | Upgrade |
Operating Margin | 4.61% | 7.49% | 7.02% | 7.64% | 6.30% | 6.44% | Upgrade |
Profit Margin | 1.70% | 4.67% | 0.10% | -1.38% | 8.00% | 4.42% | Upgrade |
Free Cash Flow Margin | -21.04% | 5.90% | 3.95% | 7.18% | 5.83% | -3.98% | Upgrade |
EBITDA | 6,946 | 8,883 | 8,653 | 8,567 | 7,391 | 6,824 | Upgrade |
EBITDA Margin | 8.14% | 10.93% | 10.40% | 10.57% | 9.29% | 9.54% | Upgrade |
D&A For EBITDA | 3,012 | 2,797 | 2,813 | 2,380 | 2,377 | 2,221 | Upgrade |
EBIT | 3,934 | 6,086 | 5,840 | 6,187 | 5,014 | 4,604 | Upgrade |
EBIT Margin | 4.61% | 7.49% | 7.02% | 7.64% | 6.30% | 6.44% | Upgrade |
Effective Tax Rate | - | 2.92% | 95.84% | - | - | 16.16% | Upgrade |
Advertising Expenses | - | 1,230 | 1,569 | 1,224 | 858.02 | 588.21 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.